Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07674745 · ClinicalTrials.gov registry record · Phase 2
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT07674745 is a Phase 2 study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 52 participants.
The verdict
NCT07674745, a Phase 2 study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Rituximab
- DRUG Intravenous immunoglobulin
- DRUG Treatment as Usual
- OTHER Therapeutic Plasma Exchange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07674745
The ClinicalTrials.gov registry entry for NCT07674745 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.
NCT07674745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07674745 about?
NCT07674745 is a clinical study titled "Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis". This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT07674745?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2026-10-01. Estimated completion is 2031-03-31.
What interventions are being tested in trial NCT07674745?
The interventions under investigation include: Rituximab (DRUG), Intravenous immunoglobulin (DRUG), Treatment as Usual (DRUG), Therapeutic Plasma Exchange (OTHER).
Who is sponsoring clinical trial NCT07674745?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.